Crinetics Pharmaceuticals, Inc. filings document a commercial-stage pharmaceutical company focused on endocrine diseases and endocrine-related tumors. Its 8-K reports include financial results and business updates tied to PALSONIFY product revenue, clinical development activity, regulatory matters, and corporate presentations. The filings also identify the company’s common stock, traded under CRNX on the Nasdaq Global Select Market.
Crinetics’ regulatory record also includes proxy materials covering governance and executive compensation, as well as current reports on officer responsibilities, executive departures, consulting arrangements, and changes in the company’s independent registered public accounting firm. These disclosures place PALSONIFY commercialization and endocrine pipeline development within formal reporting categories for operations, governance, controls, and capital-market status.
Crinetics Pharmaceuticals, Inc. has a significant shareholder group led by Wellington Management entities, which collectively report beneficial ownership of 7,131,084 shares of Common Stock, representing 6.76% of the class. These shares are held of record by clients of one or more Wellington investment advisers, with Wellington Management Group LLP positioned as the ultimate parent holding company.
The Wellington complexes report no sole voting or dispositive power, instead indicating shared voting power over 6,310,651 shares and shared dispositive power over 7,131,084 shares. The filing states that the economic interests belong to advisory clients, and no single client is known to hold more than five percent of the class.
Crinetics Pharmaceuticals, Inc. reported that President & CEO Richard Scott Struthers exercised stock options on August 7, 2026 to acquire a total of 19,928 shares of common stock through four option exercises. The options had exercise prices of $25.19, $22.61, $20.02, and $15.29 per share. Indirect holdings include common stock held by multiple family trusts and a charitable trust, with examples such as 136,805 shares held by Family Trust 1 and 80,000 shares held by a Charitable Trust. No sales of common stock are reported in this filing.
FMR LLC and Abigail P. Johnson report beneficial ownership of CRINETICS PHARMACEUTICALS INC common stock on an amended Schedule 13G. FMR LLC reports beneficial ownership of 1,439,890.88 shares, representing 1.4% of the common stock outstanding, with 1,438,730.00 shares having sole voting power and 1,439,890.88 shares subject to sole dispositive power.
Abigail P. Johnson reports no sole or shared voting power, but reports 1,439,890.88 shares subject to sole dispositive power, also equal to 1.4% of the class. The filing notes that one or more other persons have rights to receive dividends or sale proceeds for these shares, and no such person has more than five percent of the outstanding common stock.
Crinetics Pharmaceuticals reported second-quarter 2026 total revenue of $25,118 (in thousands), driven by $24,038 (in thousands) of net product revenue from its first commercial drug, PALSONIFY for acromegaly, and $1,080 (in thousands) of collaboration and license revenue. The quarter’s net loss was $120,855 (in thousands), with research and development expenses of $99,850 (in thousands) and selling, general and administrative expenses of $57,573 (in thousands).
As of June 30, 2026, Crinetics held $55,498 (in thousands) of cash and cash equivalents and $1,150,275 (in thousands) of investment securities, totaling about $1.2 billion in cash, cash equivalents and investment securities, which the company believes is sufficient to fund operations for at least the next 12 months. In January 2026 it raised approximately $380,000 (in thousands) of net proceeds through an underwritten equity offering.
On July 6, 2026, Crinetics entered into a Merger Agreement under which Vertex Pharmaceuticals will acquire Crinetics for $85.00 per share in cash. The deal is expected to close in the third quarter of 2026, subject to shareholder approval, U.S. and foreign antitrust clearances, and other customary conditions. All unvested stock options and RSUs will fully vest at closing and be cashed out if in-the-money, and Crinetics may owe a termination fee of approximately $350.5 million to Vertex if the agreement is terminated under specified circumstances.
Crinetics Pharmaceuticals agreed to be acquired by Vertex Pharmaceuticals for $85.00 per share in cash, implying a total equity value of about $10.0 billion, or $8.8 billion net of estimated cash acquired. Closing is anticipated in the third quarter of 2026, subject to regulatory approvals and approval by Crinetics stockholders.
For the quarter ended June 30, 2026, Crinetics reported $25.1 million in revenue, up from $1.0 million a year earlier, including $24.0 million in net product revenue from PALSONIFY. Net loss was $120.9 million, or $1.14 per share. Cash, cash equivalents and investment securities totaled $1.2 billion at June 30, 2026.
The company highlighted PALSONIFY commercial uptake, with 245 enrollment forms in the quarter, 385 unique prescribers within the first three quarters of launch, and over 70% of treated patients on reimbursed therapy. Crinetics also received U.S. FDA Rare Pediatric Disease Designation for atumelnant in classic congenital adrenal hyperplasia.
Crinetics Pharmaceuticals, Inc. has a large shareholder group led by Farallon Capital Management, L.L.C., which reports beneficial ownership of 8,989,098 Shares of common stock as of June 30, 2026. This position represents 8.5% of Crinetics’ outstanding common stock.
The Shares are held across several investment partnerships collectively referred to as the Farallon Funds, for which Farallon Capital Management acts as investment manager. Multiple senior members of Farallon, including Joshua J. Dapice and Hannah E. Dunn, are listed as reporting persons with shared voting and dispositive power over 8,989,098 Shares. The Farallon Funds have the right to receive dividends and sale proceeds from these securities.
Crinetics Pharmaceuticals is asking shareholders to approve a merger in which Clark Merger Sub, a wholly owned subsidiary of Vertex Pharmaceuticals, will merge with Crinetics, leaving Crinetics as a wholly owned Vertex subsidiary. At closing, each outstanding share of Crinetics common stock (other than excluded and appraisal shares) will be converted into the right to receive $85.00 in cash per share, without interest and subject to withholding taxes. Crinetics’ stock will cease trading on Nasdaq and the company will stop filing SEC reports.
The special meeting will be held virtually on August 28, 2026. Approval of the merger requires the affirmative vote of at least a majority of the 106,095,205 shares outstanding as of July 27, 2026. The board, after receiving fairness opinions from J.P. Morgan and Leerink Partners and consulting legal counsel, unanimously determined the merger and related transactions are fair and in shareholders’ best interests and recommends voting FOR the merger, a non‑binding advisory vote on merger‑related executive compensation, and a proposal to adjourn the meeting if more time is needed to solicit votes. Shareholders who do not vote for the merger and follow Delaware procedures may seek appraisal rights.
Crinetics Pharmaceuticals, Inc. has agreed to be acquired by Vertex Pharmaceuticals Incorporated through a merger in which Vertex’s wholly owned subsidiary, Clark Merger Sub, Inc., will merge with and into Crinetics. At closing, each share of Crinetics common stock will be converted into the right to receive $85.00 in cash per share, without interest and subject to withholding taxes, unless appraisal rights are properly exercised under Section 262 of the DGCL.
Crinetics’ board unanimously determined the merger and related transactions are fair and in the best interests of shareholders, approved the Merger Agreement dated July 6, 2026, and recommends voting FOR the merger proposal, the advisory compensation proposal, and the adjournment proposal. Completion requires approval by holders of at least a majority of outstanding shares entitled to vote and satisfaction of regulatory and other conditions. If the merger is not completed, Crinetics will remain an independent public company, and in certain termination scenarios it must pay Vertex a $350,474,425 cash termination fee.
Crinetics Pharmaceuticals, Inc. describes new Non-Compete Agreements entered into on July 6, 2026 with key employees in connection with its previously announced Merger Agreement with Vertex Pharmaceuticals Incorporated. The merger will combine Crinetics with a wholly owned Vertex subsidiary, with Crinetics surviving as a wholly owned subsidiary of Vertex.
Under these Non-Compete Agreements, Crinetics’ President and CEO R. Scott Struthers, CFO Tobin Schilke, Chief Scientific Officer Stephen Betz, and Chief Commercial Officer Isabel Kalofonos agree that for one year immediately following the merger closing date they will not perform services in any capacity for specified restricted businesses in territories where Crinetics conducts business as of closing. In consideration for these commitments, on the merger closing date Mr. Schilke, Dr. Betz and Ms. Kalofonos will receive cash payments of $140,000, $30,000 and $30,000, respectively.
The report also includes extensive forward-looking statement disclosures and outlines that Crinetics plans to file preliminary and definitive proxy statements so its stockholders can vote on approval of the proposed transaction with Vertex.
Crinetics Pharmaceuticals director Vivaldi Coelho Rogerio sold 3,000 shares of Common Stock in an open-market transaction at $40.00 per share. The trade occurred on July 2, 2026 and was executed automatically under a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2025. Following this sale, he directly holds 19,225 Crinetics shares.